Edition:
United States

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

8.55USD
22 Jun 2018
Change (% chg)

$0.05 (+0.59%)
Prev Close
$8.50
Open
$8.50
Day's High
$8.65
Day's Low
$8.30
Volume
1,293,498
Avg. Vol
28,710
52-wk High
$11.90
52-wk Low
$3.90

Chart for

About

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company... (more)

Overall

Beta: 0.64
Market Cap(Mil.): $136.71
Shares Outstanding(Mil.): 18.60
Dividend: --
Yield (%): --

Financials

  ALDX.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -1.47 -- --
ROI: -72.27 2.00 14.38
ROE: -75.02 3.49 16.08

BRIEF-Aldeyra Therapeutics Announces Q1 Loss Per Share $0.43

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 15 2018

BRIEF-Aldeyra Therapeutics Appoints David Mcmullin As Senior Vice President, Corporate Development And Strategy

* ALDEYRA THERAPEUTICS APPOINTS DAVID MCMULLIN AS SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT AND STRATEGY Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 10 2018

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Allergic Conjunctivitis Phase 3 Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN ALLERGIC CONJUNCTIVITIS PHASE 3 CLINICAL TRIAL

Apr 24 2018

BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs

* ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES

Feb 27 2018

BRIEF-Aldeyra Therapeutics Announces First Patient Enrolled In Dry Eye Disease Phase 2B Clinical Trial

* ALDEYRA THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN DRY EYE DISEASE PHASE 2B CLINICAL TRIAL Source text for Eikon: Further company coverage:

Jan 30 2018

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $122.84 +1.39
Novartis AG (NOVN.S) CHF75.60 +0.10
Pfizer Inc. (PFE.N) $36.51 +0.21
AbbVie Inc (ABBV.N) $93.49 -2.06
Amgen, Inc. (AMGN.OQ) $185.15 -0.84
Bristol-Myers Squibb Co (BMY.N) $55.14 +1.20
Bristol-Myers Squibb Co (BMYMP.PK) $919.60 +10.15
UCB SA (UCB.BR) €67.34 +0.22

Earnings vs. Estimates